Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1990 Sep;53(9):754–763. doi: 10.1136/jnnp.53.9.754

The effects of cyproheptadine on locomotion and on spasticity in patients with spinal cord injuries.

M Wainberg 1, H Barbeau 1, S Gauthier 1
PMCID: PMC1014252  PMID: 2246657

Abstract

The effects of cyproheptadine, a serotonergic antagonist, were studied in seven patients with spastic paresis of spinal origin. Six patients were included in a double blind crossover trial (maximal dose 24 mg/day). The patients were evaluated on both their spasticity and locomotor function. Four of the patients also participated in an open trial in which cyproheptadine was administered for a minimum of six months at optimal dose. Patients walked on a treadmill at full weight bearing when possible, or with 40% of their body weight externally supported, as required, by an overhead harness system. Cyproheptadine considerably decreased the sustained ankle clonus and episodes of spontaneous spasms observed in all the patients who previously presented these manifestations of spasticity. Two patients who required body weight support (BWS) during locomotion could walk at full weight bearing during cyproheptadine therapy. A more normal timing of EMG patterns in these patients during cyproheptadine therapy was associated with temporal distance changes and marked improvement of joint angular displacement. In contrast, the other patients showed marginal changes in the EMG and the kinematic pattern but eventually managed to walk at a higher speed. These preliminary results suggest that cyproheptadine can reduce spasticity and enhance locomotor function in spinal cord injured patients.

Full text

PDF
754

Images in this article

760Image
on p.760

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbeau H., Richards C. L., Bédard P. J. Action of cyproheptadine in spastic paraparetic patients. J Neurol Neurosurg Psychiatry. 1982 Oct;45(10):923–926. doi: 10.1136/jnnp.45.10.923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barbeau H., Rossignol S. The effects of serotonergic drugs on the locomotor pattern and on cutaneous reflexes of the adult chronic spinal cat. Brain Res. 1990 Apr 23;514(1):55–67. doi: 10.1016/0006-8993(90)90435-e. [DOI] [PubMed] [Google Scholar]
  3. Brandstater M. E., de Bruin H., Gowland C., Clark B. M. Hemiplegic gait: analysis of temporal variables. Arch Phys Med Rehabil. 1983 Dec;64(12):583–587. [PubMed] [Google Scholar]
  4. Carlsö S., Dahlöf A. G., Holm J. Kinetic analysis of the gait in patients with hemiparesis and in patients with intermittent claudication. Scand J Rehabil Med. 1974;6(4):166–179. [PubMed] [Google Scholar]
  5. Fung J., Barbeau H. A dynamic EMG profile index to quantify muscular activation disorder in spastic paretic gait. Electroencephalogr Clin Neurophysiol. 1989 Sep;73(3):233–244. doi: 10.1016/0013-4694(89)90124-7. [DOI] [PubMed] [Google Scholar]
  6. Holden M. K., Gill K. M., Magliozzi M. R., Nathan J., Piehl-Baker L. Clinical gait assessment in the neurologically impaired. Reliability and meaningfulness. Phys Ther. 1984 Jan;64(1):35–40. doi: 10.1093/ptj/64.1.35. [DOI] [PubMed] [Google Scholar]
  7. Hounsgaard J., Kiehn O. Ca++ dependent bistability induced by serotonin in spinal motoneurons. Exp Brain Res. 1985;57(2):422–425. doi: 10.1007/BF00236551. [DOI] [PubMed] [Google Scholar]
  8. Mizrahi J., Braun Z., Najenson T., Graupe D. Quantitative weightbearing and gait evaluation of paraplegics using functional electrical stimulation. Med Biol Eng Comput. 1985 Mar;23(2):101–107. doi: 10.1007/BF02456745. [DOI] [PubMed] [Google Scholar]
  9. Mizrahi J., Susak Z., Heller L., Najenson T. Objective expression of gait improvement of hemiplegics during rehabilitation by time-distance parameters of the stride. Med Biol Eng Comput. 1982 Sep;20(5):628–634. doi: 10.1007/BF02443413. [DOI] [PubMed] [Google Scholar]
  10. Myslinski N. R., Anderson E. G. The effect of serotonin precursors on alpha- and gamma-motoneuron activity. J Pharmacol Exp Ther. 1978 Jan;204(1):19–26. [PubMed] [Google Scholar]
  11. Nygren L. G., Fuxe K., Jonsson G., Olson L. Functional regeneration of 5-hydroxytryptamine nerve terminals in the rat spinal cord following 5, 6-dihydroxytryptamine induced degeneration. Brain Res. 1974 Oct 4;78(3):377–394. doi: 10.1016/0006-8993(74)90922-6. [DOI] [PubMed] [Google Scholar]
  12. Segu L., Calas A. The topographical distribution of serotoninergic terminals in the spinal cord of the cat: quantitative radioautographic studies. Brain Res. 1978 Sep 29;153(3):449–464. doi: 10.1016/0006-8993(78)90331-1. [DOI] [PubMed] [Google Scholar]
  13. Shibuya T., Anderson E. G. The influence of chronic cord transection on the effects of 5-hydroxytryptophan, l-tryptophan and pargyline on spinal neuronal activity. J Pharmacol Exp Ther. 1968 Nov;164(1):185–190. [PubMed] [Google Scholar]
  14. Visintin M., Barbeau H. The effects of body weight support on the locomotor pattern of spastic paretic patients. Can J Neurol Sci. 1989 Aug;16(3):315–325. doi: 10.1017/s0317167100029152. [DOI] [PubMed] [Google Scholar]
  15. Wainberg M., Barbeau H., Gauthier S. Quantitative assessment of the effect of cyproheptadine on spastic paretic gait: a preliminary study. J Neurol. 1986 Oct;233(5):311–314. doi: 10.1007/BF00314166. [DOI] [PubMed] [Google Scholar]
  16. White S. R., Neuman R. S. Facilitation of spinal motoneurone excitability by 5-hydroxytryptamine and noradrenaline. Brain Res. 1980 Apr 21;188(1):119–127. doi: 10.1016/0006-8993(80)90561-2. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES